Xu is passionate about understanding information and knowledge related to biopharma industry. She is bilingual in Mandarin and English. Prior to this, Xu worked as a medical writer and wrote publications based on data from clinical trials for a wide range of therapeutic areas for global pharmaceutical companies. She holds a Master degree in Medical Pharmaceutical Science from University of Groningen and a PhD degree in Biomedical Science from Vrije Universiteit Amsterdam in the Netherlands.
Latest from Xu Hu
Everest Medicine obtains selected commercialization rights to first-in-class, Phase III stage bispecific peptide MT1013 from Shanxi Micot Technology at home. A trial for secondary hyperparathyroidism is due to be completed by year-end in China.
By accepting qualified data from overseas trials to support drug registration in China, recently revised regulations for the implementation of the country’s Drug Administration Law aim to solidify regulatory pathways for use of such data and the more efficient market entry of innovative drugs.
Following the recent acceptance of a China NDA for first-in-class drug denifanstat for acne in China, Ascletis has announced positive topline results from an open-label Phase III trial focusing on the product’s long-term safety.
Newly revised regulations for the implementation of China’s Drug Administration Law transition to a market authorization holder/product-centered regulatory approach in response to the rapidly changing biopharma environment.
HUTCHMED sees good potential for its Syk inhibitor in autoimmune setting following positive topline Phase III results, with China NDA planned in first half.
Following Ribo Life Science’s recent Hong Kong IPO, an investor shares views with Scrip on the prospects for China's siRNA developers and likely deal trends in 2026.